|
|
 |
|
Viewing report
|
|
|
|
Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017
GBI Research, Feb 2012, Pages: 290
Leading business intelligence provider GBI Research has released its latest research report, “Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017”, which provides insight about immunomodulators sales forecasts until 2017.I Immunomodulators markets in the key geographies of the US, Europe and other relevant regions are also covered in the report, as are immunomodulators R&D pipelines. The report provides in-depth analysis and market forecasts of the major drug classes, which include immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, and antimetabolites), and immunostimulants (antibodies, interferon alpha and vaccines). The report also explores the competitive landscape, with a competitive analysis of the top companies in the market.
GBI Research analysis estimated the global immunomodulators market to be valued at $145.9 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 13.1% between 2002 and 2010. The market is forecast to grow at a CAGR of 8.6% between 2010 and 2017, to reach $259.3 billion in 2017.
In-depth analysis in the report is based on propriety databases, primary and secondary research and in–house analysis by the GBI Research team of experts.
GBI Research analysis found the R&D pipeline for the immunomodulators market to be strong. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that R&D activity for immunomodulators will remain active for at least next four to five years.
Scope
- Data and analysis of the immunomodulators market in the leading geographies of the US and Europe. Different drug classes of immunomodulators discussed in the report are immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, antimetabolites) and immunostimulants (antibodies, interferon alpha and vaccines).
- Annualized market data for the immunomodulators market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes
- Key drivers and restraints that have had significant impact on the market.
- Competitive landscape of the global immunomodulators market including benchmarking of the top companies. The key companies studied in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Bristol-Myers Squibb, Eli Lilly.
Reasons to buy
- Build effective strategies to launch pipeline products, by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of the top competitors.
- Develop market-entry and market expansion strategies, by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first–in-class molecules with improved efficacy and safety profiles.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
